3 Promising Penny Stocks With Market Caps Under $2B

As U.S. markets rise amidst a wave of earnings reports and ongoing tariff discussions, investors are keenly observing how these factors impact various sectors. In this landscape, penny stocks—often seen as relics of past market eras—continue to offer intriguing opportunities for those seeking exposure to smaller or newer companies. When backed by strong financial health, these stocks can provide a mix of affordability and growth potential that might appeal to investors looking for promising additions to their portfolios.

Top 10 Penny Stocks In The United States

Click here to see the full list of 414 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Taboola.com (TBLA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taboola.com Ltd. operates an artificial intelligence-based algorithmic engine platform across various countries including Israel, the United States, the United Kingdom, and Germany, with a market cap of approximately $1.04 billion.

Operations: The company does not report specific revenue segments.

Market Cap: $1.04B

Taboola.com Ltd. has demonstrated financial resilience, achieving profitability over the past year with a market cap of US$1.04 billion. The company's debt is well-covered by operating cash flow, and it maintains more cash than total debt, enhancing its financial stability. Despite a low return on equity of 1.5%, Taboola's earnings are forecasted to grow significantly at 74.16% annually. Recent initiatives like DeeperDive and Predictive Audiences highlight Taboola's focus on leveraging AI for enhanced user engagement and monetization opportunities, potentially driving future growth in revenue streams projected between US$1,858 million and US$1,888 million for 2025.

• Click to explore a detailed breakdown of our findings in Taboola.com's financial health report.
• Explore Taboola.com's analyst forecasts in our growth report.

United States Antimony (UAMY)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: United States Antimony Corporation engages in the production and sale of antimony, zeolite, and precious metals in the United States and Canada, with a market cap of $409.71 million.

Operations: The company generates revenue from its Antimony segment, contributing $15.43 million, and its Zeolite segment, which adds $3.43 million.

Market Cap: $409.71M

United States Antimony Corporation, with a market cap of US$409.71 million, has shown significant revenue from its antimony and zeolite segments. The company is strategically expanding its supply chain by securing antimony sources from Alaska, Australia, Bolivia, Canada, and Mexico to support its smelters in Montana and Mexico. Despite being unprofitable currently, the firm has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt. Recent inclusion in multiple Russell indices reflects growing investor interest. However, challenges remain due to high impurities in some ore supplies affecting processing costs.

• Click here and access our complete financial health analysis report to understand the dynamics of United States Antimony.
• Gain insights into United States Antimony's future direction by reviewing our growth report.

ATRenew (RERE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ATRenew Inc. operates a pre-owned consumer electronics transactions and services platform in China, with a market cap of approximately $754.79 million.

Operations: The company generates revenue from its retail electronics segment, amounting to CN¥17.33 billion.

Market Cap: $754.79M

ATRenew Inc., with a market cap of approximately $754.79 million, has demonstrated financial resilience by becoming profitable in the last year, reporting CN¥42.8 million net income for Q1 2025 compared to a loss previously. The company maintains robust liquidity with short-term assets exceeding liabilities and more cash than total debt, while its operating cash flow covers debt comfortably. Recent announcements include a $50 million share repurchase program funded from existing cash reserves, reflecting confidence in its financial health. Despite these strengths, the company's return on equity remains low at 3.4%, indicating room for improvement in profitability metrics.

• Unlock comprehensive insights into our analysis of ATRenew stock in this financial health report.
• Assess ATRenew's future earnings estimates with our detailed growth reports.

Turning Ideas Into Actions

• Dive into all 414 of the US Penny Stocks we have identified here.
• Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com